We perform critical-point analysis for three-variable systems that represent essential processes of the growth of the angiogenic tumor, namely, tumor growth, vascularization, and generation of angiogenic factor (protein) as a function of effective vessel density. Two models that describe tumor growth depending on vascular mass and regulation of new vessel formation through a key angiogenic factor are explored. The first model is formulated in terms of ODEs, while the second assumes delays in this regulation, thus leading to a system of DDEs. In both models, the only nontrivial critical point is always unstable, while one of the trivial critical points is always stable. The models predict unlimited growth, if the initial condition is close enough to the nontrivial critical point, and this growth may be characterized by oscillations in tumor and vascular mass. We suggest that angiogenesis per se does not suffice for explaining the observed stabilization of vascular tumor size.
29 May 2021 in Journal of Cancer Research and Clinical Oncology
Chemotherapy remains a widely used cancer treatment. Acquired drug resistance may greatly reduce the efficacy of treatment and means to overcome it are a topic of active discussion among researchers. One of the proposed solutions is to shift the therapeutic paradigm from complete eradication of cancer to maintenance, i.e., to treat it as a chronic disease. A concept of metronomic therapy (low chemotherapy doses applied continuously) emerged in early 2000s and was henceforth shown to offer a number of benefits, including targeting endothelial cells and reducing acquired drug resistance. Using mathematical modeling and optimal control techniques, we investigate the hypothesis that lower doses of chemotherapy are beneficial for patients. Our analysis of a mathematical model of tumor growth under angiogenic signaling proposed by Hahnfeldt et al. adapted to heterogeneous tumors treated by combined anti-angiogenic agent and chemotherapy offers insights into the effects of metronomic therapy. Firstly, assuming constant long-term drug delivery, the model suggests that the longest survival time is achieved for intermediate drug doses. Secondly, by formalizing the notion of the therapeutic target being maintenance rather than eradication, we show that in the short term, optimal chemotherapy scheduling consists mainly of a drug applied at a low dose. In conclusion, we suggest that metronomic therapy is an attractive alternative to maximum tolerated dose therapies to be investigated in experimental settings and clinical trials.
1 April 2011 in Journal of Mathematical Analysis and Applications
We investigate a general class of linear models of dyadic interactions with a constant discrete time delay. We prove that the changes in stability of the stationary states occur for various intervals of the parameters that determine the strength and nature of emotional interactions between the partners. The dynamics of interactions depend on both reactivity of partners to their own emotional states as well as to the partner's states. The results suggest that reactivity to the partner's states has greater impact on the dynamics of the relationship than the reactivity to one's own states. Moreover, the results underscore the importance of deliberation in maintaining the stability of the relationship. Moreover, we have found that multiple stability switches are only possible when one of the partners reacts with delay to their own emotional states. We also propose a generalization to triadic interactions.